The Tissue-Tek Genie Advanced Staining System is the first and only fully automated, true random access stainer for immunohistochemistry (IHC) and in situ hybridisation (ISH); allowing any IHC or ISH capsule or probe to be loaded at any time on any station.
Imagine, one single standardising solution, enabling uncompromisingly fast results and providing you with the exact same predictable turnaround time.
Scientists have discovered that cervical cancer can be divided into 2 distinct molecular subgroups – one far more aggressive than the other – as part of the largest ‘omics’ study of its kind.
The tall cell variant (TCV) is an aggressive subtype of papillary thyroid carcinoma (PTC). Sebastian Stenman, researcher from the Institute for Molecular Medicine, and the Department of Pathology at the University of Helsinki, Finland, is developing and training a deep learning algorithm using supervised learning to detect and quantify the proportion of tall cells in PTC.
Renal cell carcinoma is among the fifteen most common cancers worldwide. Dr Titus Brinker, from the German Cancer Research Center (DKFZ), looked at whether a convolutional neural network (CNN) can extract relevant image features from a typical H&E-stained slide to predict 5-year overall survival.
Clinical management of soft tissue sarcoma is particularly challenging. Dr Sebastian Foersch, researcher at the Institute of Pathology at the University Medical Center in Mainz, Germany, has used a deep learning model for diagnosis and prognosis prediction of soft tissue sarcoma using conventional histopathology slides.
As more genomic alterations become targets for therapy, health institutions and hospitals are creating specialist Molecular Tumour Boards to support better decision-making for patient care. This evolving team, and its role, was highlighted in a presentation at the 34th European Congress of Pathology in Basel, Switzerland.
Deaths from cancer are currently estimated at 10 million each year worldwide. Conventional cancer staging systems aim to categorize patients into different groups with distinct outcomes. ‘However, even within a specific stage, there is often substantial variation in patient outcomes,’ Markus Plass, academic researcher from the Medical University of Graz, Austria, explained to Healthcare in…
LabBook provides an overview of European laboratory systems. Whether you are about to set up a new lab or want to replace existing equipment, LABBook will help you make smart investment decisions to boost efficiency and productivity in your lab.
Imagine a new quality standard that improves the lives of patients and lab professionals in cancer care.
Histopathology company Sakura Finetek Europe announces the launch of its newest solution Tissue-Tek Genie, an advanced staining system, entering a new market.
Advanced staining evolved with growing complexity, resulting in many variations and combinations to get the right staining quality. It felt the flexibility brings you total control, but actually what we see is the introduction of multiple variables. This endless tweaking has taken its toll.
The development of a simple blood test for glioblastomas could mean earlier diagnosis and more effective and personalised treatment options against the most common type of malignant brain cancer.
Researchers have identified an enzyme that is a promising new therapeutic target to combat the dangerous bacterial disease melioidosis.
Researchers in Sweden have now discovered a faster and easier way to determine who has an aggressive form of prostate cancer, and who has not.
By comparing the neutralisation capacity induced by the different variants of SARS-CoV-2, a team from Geneva reveals the exceptional capacity of Omicron to evade our immunity.
Researchers from Boston University School of Medicine have developed a novel artificial intelligence algorithm to assess digital pathology data.
A new way of differentiating healthy from diseased cells could pave the way for more personalised treatment for patients diagnosed with glioblastoma multiforme (GBM), a common and aggressive type of brain tumour.
SARS-CoV-2 has heavily impacted global society with high pressure on public health and economics. MolGen is proud to assist in relieving some of the pressure and support the testing framework.
